Astellas Pharma Canada, Inc. is committed to providing patients, customers, community and employees with a bright future by changing tomorrow. This commitment is made possible because it is a different kind of pharmaceutical company. Headquartered in Markham, Ontario, Astellas Pharma Canada, Inc. is recognized as the first Japanese pharmaceutical company in Canada.

**PROJECT PURPOSE**

The purpose of this multi-centre, randomized, placebo-controlled study is to assess the use of mirabegron for the treatment of neurogenic bladder dysfunction.

**TECHNOLOGY OVERVIEW**

People with spinal cord injury (SCI) often suffer from neurogenic bladder dysfunction, causing symptoms of urinary urgency, increased urinary frequency and urinary incontinence, which can significantly reduce their quality of life. This is commonly treated with anticholinergic medication, which is associated with undesirable side effects including dry mouth, cognitive changes and constipation. Mirabegron is a new medication for overactive bladder that causes bladder relaxation, which may be able to reduce negative bladder symptoms for SCI patients with minimal side effects.
**PROJECT TEAM**

**Principal Investigator**
Dr. Blayne Welk, Western University  
Dr. Karen Ethans, University of Manitoba

**Investigative Team**
Dr. Alan Casey, University of Manitoba  
Dr. Robert Bard, University of Manitoba  
Dr. Michael Namaka, University of Manitoba  
Jessie Shea, University of Manitoba  
Mary McKibbon, St. Joseph’s Hospital

**Contact**
Rob Hickling  
Director, IT & Commercialization  
604-827-1681  
rhickling@rickhanseninstitute.org

**Learn More**
rickhanseninstitute.org  
astellas.ca

---

**TIMELINE**

- **Enrollment currently underway**
- **Recruiting 144 subjects**
- **10 weeks study duration for each subject (intervention & follow-up)**

**NEXT STEPS**

The need for a larger clinical trial will be assessed based on the data from this study.

---

This project (G2015-12 and G2015-13) is supported through a contribution from Western Economic Diversification Canada. The views expressed herein represent the views of the Rick Hansen Institute.

The Rick Hansen Institute is a Canadian-based not-for-profit organization with the goal of creating a world without paralysis after spinal cord injury. It works towards this goal by accelerating research and translating clinical findings into practical solutions to develop new treatments, improve health care outcomes, reduce long-term costs and improve the quality of life for those living with spinal cord injury. www.rickhanseninstitute.org